Wheel vs Biogen
Side-by-side comparison of AI visibility scores, market position, and capabilities
Wheel is a telehealth infrastructure company providing the clinician network, technology, and operations that companies need to build and scale virtual care programs.
About
Wheel is a telehealth infrastructure company founded in 2017 that provides the clinical workforce, technology platform, and operational services that enable businesses to build and power virtual care programs. The company operates as a B2B platform serving healthcare companies, retailers, insurers, and employers that want to offer telehealth services without building a clinical workforce from scratch. Wheel provides access to a nationwide network of licensed clinicians including physicians, nurse practitioners, and physician assistants who can be deployed to power telehealth products across medical, behavioral health, and chronic care specialties. The platform handles clinician credentialing, scheduling, documentation workflows, and state licensure management so that clients can focus on patient experience and growth. Wheel raised over $160M and has powered telehealth programs for companies including retailers launching pharmacy and health clinics and digital health companies scaling their clinical capacity rapidly. As telehealth has become embedded in mainstream healthcare delivery, Wheel enables organizations to participate in virtual care without the complexity of building clinical operations infrastructure internally.
Cambridge MA neuroscience biopharma (NASDAQ: BIIB) at $9.7B 2024 revenue; LEQEMBI $87M Q4 (Alzheimer's first-in-class amyloid therapy), SKYCLARYS $102M Q4 (Friedreich's ataxia), MS franchise declining vs. Eli Lilly donanemab.
About
Biogen Inc. is a Cambridge, Massachusetts-based neuroscience biopharmaceutical company — publicly traded on NASDAQ (NASDAQ: BIIB) as an S&P 500 Health Care component — researching, developing, and commercializing therapies for neurological, neurodegenerative, and neurodevelopmental diseases including Alzheimer's disease, multiple sclerosis, spinal muscular atrophy, and rare neurological conditions through approximately 7,400 employees worldwide. In fiscal year 2024, Biogen reported total revenue of $9.7 billion (-2% year-over-year) and GAAP diluted EPS of $11.18 (+40%), reflecting significant cost-cutting that improved profitability despite modest revenue decline. Revenue decline was driven by continued erosion in the core multiple sclerosis franchise (TECFIDERA, AVONEX, TYSABRI facing generic and biosimilar competition) while new product revenue grew: LEQEMBI (lecanemab, Alzheimer's disease, partnered with Eisai) generated approximately $87 million in Q4 2024 global sales — reflecting the slow but building commercial trajectory of the first drug to slow Alzheimer's cognitive decline — and SKYCLARYS (omaveloxolone, Friedreich's ataxia) generated $102 million in Q4, nearly double the year-earlier period. CEO Christopher Viehbacher, who joined in 2022 from Genentech's parent Roche, has led a strategic restructuring that includes cost reduction, pipeline refocus on high-probability neurology programs, and the LEQEMBI commercial execution through a partnership model with Eisai.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.